Overview

• Hims & Hers posted Q1 earnings of $0.20 per share and $586 million in revenue, exceeding Wall Street expectations and marking 111% year-over-year growth.
• Subscriber base grew 38% to 2.37 million, slightly below analyst forecasts, with average monthly revenue per subscriber rising 53% to $84.
• Q2 revenue guidance of $530–$550 million fell short of the $564 million consensus, contributing to a 5% drop in after-hours stock trading.
• The company will cease compounded semaglutide sales by May 22, transitioning to branded Wegovy through a partnership with Novo Nordisk.
• Hims & Hers appointed former Amazon executive Nader Kabbani as COO and reaffirmed its 2030 targets of $6.5 billion in revenue and $1.3 billion in adjusted EBITDA.